GoodRx Holdings (GDRX) Net Cash Flow (2019 - 2026)

GoodRx Holdings has disclosed Net Cash Flow across 8 years of filings, most recently posting $60.4 million for Q2 2026.

• In Q2 2026, Net Cash Flow rose 407.19% year-over-year to $60.4 million; the TTM figure through Jun 2026 stood at $14.8 million (up 106.07% YoY), while the FY2025 annual figure was -$186.5 million, up 16.71% from the prior year.
• Net Cash Flow came in at $60.4 million for Q2 2026 at GoodRx Holdings, up from -$26.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $60.4 million in Q2 2026 to a low of -$147.4 million in Q1 2025.
• Average Net Cash Flow over 5 years is -$35.8 million, with a median of -$10.1 million recorded in 2024.
• Year-over-year, Net Cash Flow surged 1976.68% in 2023 and sank 3655.01% in 2024.
• Over 5 years, Net Cash Flow stood at $28.4 million in 2022, then slumped by 532.04% to -$122.6 million in 2023, then surged by 120.04% to $24.6 million in 2024, then tumbled by 147.66% to -$11.7 million in 2025, then surged by 615.87% to $60.4 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $60.4 million in Q2 2026, -$26.1 million in Q1 2026, and -$11.7 million in Q4 2025.